10 completed, 5 terminated. 10 Phase 2, 8 Phase 1, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 7, Terminated 3 |
| Phase 1 | 8 | Completed 5, Terminated 3 |
| Early Phase 1 | 2 | Completed 1, Terminated 1 |
Follow BerGenBio ASA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene Bemcentinib, Pembrolizumab, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Terminated | BerGenBio ASA | 26 | 2023-03-03 | 2025-10-29 |
| A Study to Investigate 14C-bemcentinib in Healthy Male Subjects Bemcentinib - Non-Small Cell Lung Cancer, Metastatic Melanoma | Phase 1 | Completed | BerGenBio ASA | 6 | 2022-08-02 | 2025-01-29 |
| A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants Tilvestamab - Ovarian Neoplasms | Phase 1 | Terminated | BerGenBio ASA | 16 | 2021-02-25 | 2023-04-20 |
| A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients Bemcentinib, SoC - COVID-19 | Phase 2 | Completed | BerGenBio ASA | 115 | 2020-10-20 | 2024-10-16 |
| AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery BGB 324 (before surgery), BGB 324 (after surgery) - Brain and Central Nervous System Tumors | Early Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 10 | 2020-01-02 | 2024-02-08 |
| Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma Rucaparib, Abemaciclib, pembrolizumab & bemcentinib - Mesothelioma, Malignant | Phase 2 | Completed | University of Leicester | 186 | 2019-01-28 | 2026-08-17 |
| Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer Bemcentinib, Nab-paclitaxel, Gemcitabine - Cancer of Pancreas | Phase 1 / Phase 2 | Terminated | University of Texas Southwestern Medical Center | 9 | 2019-01-03 | 2023-11-09 |
| Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes Bemcentinib - Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 2 | Completed | GWT-TUD GmbH | 45 | 2018-12-20 | 2021-12-21 |
| A First-time-in-human Study of BGB149 BGB149, Placebo - Healthy Volunteers | Early Phase 1 | Completed | BerGenBio ASA | 24 | 2018-12-19 | 2022-03-16 |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Pembrolizumab, Bemcentinib - Lung Cancer Metastatic, NSCLC Stage IV | Phase 2 | Completed | BerGenBio ASA | 99 | 2017-10-02 | 2025-09-25 |
| Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC Bemcentinib; pembrolizumab - Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV | Phase 2 | Terminated | BerGenBio ASA | 29 | 2017-07-26 | 2021-11-09 |
| BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab - Melanoma | Phase 1 / Phase 2 | Completed | Haukeland University Hospital | 74 | 2017-02-13 | 2025-01-14 |
| Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. BGB324, Docetaxel - Non-Small Cell Lung Carcinoma | Phase 1 | Completed | University of Texas Southwestern Medical Center | 23 | 2016-11-01 | 2024-02-21 |
| A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer Erlotinib, Bemcentinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | BerGenBio ASA | 40 | 2015-04-19 | 2025-02-26 |
| A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS Bemcentinib, Cytarabine, Decitabine - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | BerGenBio ASA | 122 | 2014-10-22 | 2024-12-19 |
Carcinoma, Non-Small-Cell Lung (5) · Leukemia, Myeloid, Acute (3) · COVID-19 (2) · Glioblastoma (2) · Melanoma (2) · Mesothelioma, Malignant (2) · Myelodysplastic Syndromes (2) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Central Nervous System Neoplasms (1) · Inflammatory Breast Neoplasms (1) · Ovarian Neoplasms (1) · Triple Negative Breast Neoplasms (1)
bemcentinib (12) · pembrolizumab (5) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Cytarabine (1) · Decitabine (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Paclitaxel (1) · Pemetrexed (1) · Postoperative Period (1)
United States (8) · United Kingdom (6) · Norway (5) · Spain (3) · France (2) · Germany (2) · Italy (2) · Greece (1) · Hungary (1) · India (1) · Netherlands (1) · Poland (1) · Singapore (1) · South Africa (1) · South Korea (1)
Akil Jackson (1) · Burt Nabors, MD (1) · David E Gerber, MD (1) · Dean Fennell, PhD, FRCP (1) · Dr. Lauren Byers, MD (1) · Hani Gabra (1) · Muna Albayaty, MD (1) · Sonja Loges, MD (1) · Syed Kazmi, MD (1) · Uwe Platzbecker, Prof. (1)
PMID 33515503, PMID 35157829, PMID 35492873, PMID 40122885, PMID 40696160
2016 (2), UM1CA137443 (1)